X2S Stock Overview
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 2/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for X2S from our risk checks.
Sinopharm Group Co. Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$2.39 |
52 Week High | HK$3.25 |
52 Week Low | HK$2.02 |
Beta | 0.84 |
1 Month Change | -6.65% |
3 Month Change | 1.27% |
1 Year Change | -11.76% |
3 Year Change | 15.78% |
5 Year Change | -35.71% |
Change since IPO | 35.51% |
Recent News & Updates
Recent updates
Shareholder Returns
X2S | DE Healthcare | DE Market | |
---|---|---|---|
7D | -0.8% | -3.2% | 1.9% |
1Y | -11.8% | -1.8% | 7.3% |
Return vs Industry: X2S underperformed the German Healthcare industry which returned -1.8% over the past year.
Return vs Market: X2S underperformed the German Market which returned 7.3% over the past year.
Price Volatility
X2S volatility | |
---|---|
X2S Average Weekly Movement | 6.9% |
Healthcare Industry Average Movement | 5.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: X2S has not had significant price volatility in the past 3 months.
Volatility Over Time: X2S's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 115,959 | Yong Liu | https://www.sinopharmgroup.com.cn |
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics.
Sinopharm Group Co. Ltd. Fundamentals Summary
X2S fundamental statistics | |
---|---|
Market cap | €7.52b |
Earnings (TTM) | €1.16b |
Revenue (TTM) | €76.24b |
6.5x
P/E Ratio0.1x
P/S RatioIs X2S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
X2S income statement (TTM) | |
---|---|
Revenue | CN¥596.57b |
Cost of Revenue | CN¥548.06b |
Gross Profit | CN¥48.51b |
Other Expenses | CN¥39.46b |
Earnings | CN¥9.05b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 2.90 |
Gross Margin | 8.13% |
Net Profit Margin | 1.52% |
Debt/Equity Ratio | 57.0% |
How did X2S perform over the long term?
See historical performance and comparisonDividends
4.6%
Current Dividend Yield30%
Payout RatioDoes X2S pay a reliable dividends?
See X2S dividend history and benchmarksSinopharm Group dividend dates | |
---|---|
Ex Dividend Date | Jun 17 2024 |
Dividend Pay Date | Aug 13 2024 |
Days until Ex dividend | 81 days |
Days until Dividend pay date | 138 days |
Does X2S pay a reliable dividends?
See X2S dividend history and benchmarks